Guidelines of the International Headache Society for controlled trials of preventive treatment of migraine in children and adolescents, 1st edition

Clinical Trials Standing Committee and the Child and Adolescent Standing Committee of the International Headache Society

Research output: Contribution to journalArticle

Abstract

BACKGROUND: Because the results of clinical trials of investigational treatments influence regulatory policy, prescribing patterns, and use in clinical practice, high quality trials are an essential component of the evidence base for migraine. The International Headache Society has published guidelines for clinical trials in adults with migraine since 1991. With multiple issues specific to children and adolescents with migraine, as well as the emergence of novel trial designs and advances in pharmaceuticals, biologics, devices, and behavioural interventions, there is a need for guidance focusing on issues specific to the conduct of clinical trials in children and adolescents with migraine.

OBJECTIVES: The objective of these guidelines is to provide a contemporary, standardized, and evidence-based approach to the design, conduct, and reporting of well-controlled clinical trials of preventive treatment of migraine in children and adolescents.

METHODS: The development of these guidelines was based on guidelines previously published by the International Headache Society and regulatory bodies. The recommendations are evidence-based, where available. The process included consultations among various committees, roundtable discussions among stakeholders (lay people and the pharmaceutical industry), and open consultation with the IHS membership on the final draft.

RESULTS: A series of recommendations addressing the major issues in clinical trials in children and adolescents with migraine is provided. Recommendations are supported by evidence-based practice and validated methodologies, where available. Supporting comments are provided to clarify ambiguities.

CONCLUSIONS: These guidelines should be consulted and used in designing and conducting clinical trials of preventive treatments in children and adolescents with migraine.

Original languageEnglish
Pages (from-to)803-16
Number of pages13
JournalCephalalgia
Volume39
Issue number7
DOIs
Publication statusPublished - Apr 4 2019

Fingerprint

Migraine Disorders
Headache
Guidelines
Clinical Trials
Therapeutics
Referral and Consultation
Investigational Therapies
Evidence-Based Practice
Controlled Clinical Trials
Drug Industry
Biological Products
Equipment and Supplies
Pharmaceutical Preparations

Cite this

Clinical Trials Standing Committee and the Child and Adolescent Standing Committee of the International Headache Society (2019). Guidelines of the International Headache Society for controlled trials of preventive treatment of migraine in children and adolescents, 1st edition. Cephalalgia, 39(7), 803-16. https://doi.org/10.1177/0333102419842188

Guidelines of the International Headache Society for controlled trials of preventive treatment of migraine in children and adolescents, 1st edition. / Clinical Trials Standing Committee and the Child and Adolescent Standing Committee of the International Headache Society.

In: Cephalalgia, Vol. 39, No. 7, 04.04.2019, p. 803-16.

Research output: Contribution to journalArticle

Clinical Trials Standing Committee and the Child and Adolescent Standing Committee of the International Headache Society 2019, 'Guidelines of the International Headache Society for controlled trials of preventive treatment of migraine in children and adolescents, 1st edition', Cephalalgia, vol. 39, no. 7, pp. 803-16. https://doi.org/10.1177/0333102419842188
Clinical Trials Standing Committee and the Child and Adolescent Standing Committee of the International Headache Society. Guidelines of the International Headache Society for controlled trials of preventive treatment of migraine in children and adolescents, 1st edition. Cephalalgia. 2019 Apr 4;39(7):803-16. https://doi.org/10.1177/0333102419842188
Clinical Trials Standing Committee and the Child and Adolescent Standing Committee of the International Headache Society. / Guidelines of the International Headache Society for controlled trials of preventive treatment of migraine in children and adolescents, 1st edition. In: Cephalalgia. 2019 ; Vol. 39, No. 7. pp. 803-16.
@article{d14837cbf5fc4601a4f910a8b1a08e9d,
title = "Guidelines of the International Headache Society for controlled trials of preventive treatment of migraine in children and adolescents, 1st edition",
abstract = "BACKGROUND: Because the results of clinical trials of investigational treatments influence regulatory policy, prescribing patterns, and use in clinical practice, high quality trials are an essential component of the evidence base for migraine. The International Headache Society has published guidelines for clinical trials in adults with migraine since 1991. With multiple issues specific to children and adolescents with migraine, as well as the emergence of novel trial designs and advances in pharmaceuticals, biologics, devices, and behavioural interventions, there is a need for guidance focusing on issues specific to the conduct of clinical trials in children and adolescents with migraine.OBJECTIVES: The objective of these guidelines is to provide a contemporary, standardized, and evidence-based approach to the design, conduct, and reporting of well-controlled clinical trials of preventive treatment of migraine in children and adolescents.METHODS: The development of these guidelines was based on guidelines previously published by the International Headache Society and regulatory bodies. The recommendations are evidence-based, where available. The process included consultations among various committees, roundtable discussions among stakeholders (lay people and the pharmaceutical industry), and open consultation with the IHS membership on the final draft.RESULTS: A series of recommendations addressing the major issues in clinical trials in children and adolescents with migraine is provided. Recommendations are supported by evidence-based practice and validated methodologies, where available. Supporting comments are provided to clarify ambiguities.CONCLUSIONS: These guidelines should be consulted and used in designing and conducting clinical trials of preventive treatments in children and adolescents with migraine.",
author = "{Clinical Trials Standing Committee and the Child and Adolescent Standing Committee of the International Headache Society} and Ishaq Abu-Arafeh and Hershey, {Andrew D} and Hans-Christoph Diener and Cristina Tassorelli",
year = "2019",
month = "4",
day = "4",
doi = "10.1177/0333102419842188",
language = "English",
volume = "39",
pages = "803--16",
journal = "Cephalalgia",
issn = "0333-1024",
publisher = "SAGE Publications Ltd",
number = "7",

}

TY - JOUR

T1 - Guidelines of the International Headache Society for controlled trials of preventive treatment of migraine in children and adolescents, 1st edition

AU - Clinical Trials Standing Committee and the Child and Adolescent Standing Committee of the International Headache Society

AU - Abu-Arafeh, Ishaq

AU - Hershey, Andrew D

AU - Diener, Hans-Christoph

AU - Tassorelli, Cristina

PY - 2019/4/4

Y1 - 2019/4/4

N2 - BACKGROUND: Because the results of clinical trials of investigational treatments influence regulatory policy, prescribing patterns, and use in clinical practice, high quality trials are an essential component of the evidence base for migraine. The International Headache Society has published guidelines for clinical trials in adults with migraine since 1991. With multiple issues specific to children and adolescents with migraine, as well as the emergence of novel trial designs and advances in pharmaceuticals, biologics, devices, and behavioural interventions, there is a need for guidance focusing on issues specific to the conduct of clinical trials in children and adolescents with migraine.OBJECTIVES: The objective of these guidelines is to provide a contemporary, standardized, and evidence-based approach to the design, conduct, and reporting of well-controlled clinical trials of preventive treatment of migraine in children and adolescents.METHODS: The development of these guidelines was based on guidelines previously published by the International Headache Society and regulatory bodies. The recommendations are evidence-based, where available. The process included consultations among various committees, roundtable discussions among stakeholders (lay people and the pharmaceutical industry), and open consultation with the IHS membership on the final draft.RESULTS: A series of recommendations addressing the major issues in clinical trials in children and adolescents with migraine is provided. Recommendations are supported by evidence-based practice and validated methodologies, where available. Supporting comments are provided to clarify ambiguities.CONCLUSIONS: These guidelines should be consulted and used in designing and conducting clinical trials of preventive treatments in children and adolescents with migraine.

AB - BACKGROUND: Because the results of clinical trials of investigational treatments influence regulatory policy, prescribing patterns, and use in clinical practice, high quality trials are an essential component of the evidence base for migraine. The International Headache Society has published guidelines for clinical trials in adults with migraine since 1991. With multiple issues specific to children and adolescents with migraine, as well as the emergence of novel trial designs and advances in pharmaceuticals, biologics, devices, and behavioural interventions, there is a need for guidance focusing on issues specific to the conduct of clinical trials in children and adolescents with migraine.OBJECTIVES: The objective of these guidelines is to provide a contemporary, standardized, and evidence-based approach to the design, conduct, and reporting of well-controlled clinical trials of preventive treatment of migraine in children and adolescents.METHODS: The development of these guidelines was based on guidelines previously published by the International Headache Society and regulatory bodies. The recommendations are evidence-based, where available. The process included consultations among various committees, roundtable discussions among stakeholders (lay people and the pharmaceutical industry), and open consultation with the IHS membership on the final draft.RESULTS: A series of recommendations addressing the major issues in clinical trials in children and adolescents with migraine is provided. Recommendations are supported by evidence-based practice and validated methodologies, where available. Supporting comments are provided to clarify ambiguities.CONCLUSIONS: These guidelines should be consulted and used in designing and conducting clinical trials of preventive treatments in children and adolescents with migraine.

U2 - 10.1177/0333102419842188

DO - 10.1177/0333102419842188

M3 - Article

VL - 39

SP - 803

EP - 816

JO - Cephalalgia

JF - Cephalalgia

SN - 0333-1024

IS - 7

ER -